Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 3, 2003, Pages 507-511

  Chou, Yuo Ling ^a   Davey, David D ^a   Eagen, Keith A ^a   Griedel, Brian D ^a   Karanjawala, Rushad ^a   Phillips, Gary B ^a   Sacchi, Karna L ^a   Shaw, Kenneth J ^a   Wu, Shung C ^a   Lentz, Dao ^a   Liang, Amy M ^a   Trinh, Lan ^a   Morrissey, Michael M ^a   Kochanny, Monica J ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOBENZAMIDE; ANILINE; ANTHRANILIC ACID; BENZOTHIOPHENE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; BROMINE; CHLORINE; FLUORINE; THROMBIN; TRYPSIN;

ANTICOAGULATION; ARTICLE; CRYSTALLOGRAPHY; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTHRANILIC ACIDS; ANTICOAGULANTS; CATTLE; FACTOR XA; HETEROCYCLIC COMPOUNDS; HUMANS; INDICATORS AND REAGENTS; KINETICS; PROTHROMBIN TIME; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; THROMBIN; TRYPSIN INHIBITORS;

EID: 0037328153     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00938-1     Document Type: Article

References (23)

1. (a) Kochanny, M. J.; Adler, M.; Cheeseman, S.; Chou, Y. L.; Davey, D. D.; Eagen, K. A.; Ewing, J.; Fitch, R.; Griedel, B. D.; Karanjawala, R.; Lee, W.; Lentz, D.; Liang, A.; Morrissey, M. M.; Phillips, G. B.; Post, J.; Sacchi, K. L.; Sakata, S. T.; Shaw, K. J.; Snider, R. M.; Subramanyam, B.; Trinh, L.; Vergona, R.; Walters, J.; Wang, Y. X.; White, K. A.; Whitlow, M.; Wu, S. C.; Ye, B.; Zhao, Z. 221st National Meeting of the American Chemical Society, San Diego, CA, Apr 1-5, 2001; American Chemical Society: Washington, DC, 2001; MEDI-16.
2. (b) Kochanny, M. J.; Davey, D. D.; Eagen, K. A.; Griedel, B. D.; Karanjawala, R.; Lentz, D.; Liang, A.; Morrissey, M. M.; Phillips, G. B.; Sacchi, K. L.; Snider, R. M.; Trinh, L. 221st National Meeting of the American Chemical Society, San Diego, CA, Apr 1-5, 2001; American Chemical Society: Washington, DC, 2001; MEDI-120.
3. (c) Chou, Y. L.; Eagen, K. A.; Griedel, B. D.; Lentz, D.; Liang, A.; Morrissey, M. M.; Shaw, K. J.; Wu, S. C.; Kochanny, M. J. 221st National Meeting of the American Chemical Society, San Diego, CA, Apr 1-5, 2001; American Chemical Society: Washington, DC, 2001; MEDI-123.
4. (a) Ahmad S., Rawala-Sheikh R., Walsh P.N. Semin. Thromb. Hemost. 18:1992;311.
5. (b) Mann K.G., Nesheim M.E., Church W.R., Haley P., Krishnaswamy S. Blood. 76:1990;1.
6. (a) Harker L.A., Hanson S.R., Kelly A.B. Thromb. Haemostasis. 74:1995;464
7. (b) Hara T., Yokoyama A., Tanabe K., Ishihara H., Iwamoto M. Thromb. Haemost. 74:1995;635.
8. (a) Sanderson P.E.J. Annu. Rep. Med. Chem. 36:2001;79
9. (b) Rai R., Sprengeler P.A., Elrod K.C., Young W.B. Curr. Med. Chem. 8:2001;101
10. (c) Zhu B.Y., Scarborough B.M. Annu. Rep. Med. Chem. 35:2000;83
11. (d) Vacca J.P. Curr. Opin. Chem. Biol. 4:2000;394
12. (e) Ewing W.R., Pauls H.W., Spada A.P. Drugs Future. 24:1999;771.
13. Compound 1 was originally purchased from Maybridge Chemical Company. A recent publication from Axys Pharmaceuticals has appeared detailing their initial SAR investigations of this compound: Shrader W.D., Young W.B., Sprengeler P.A., Sangalang J.C., Elrod K., Carr G. Bioorg. Med. Chem. Lett. 11:2001;1801. Our independent results described herein are consistent with the findings of the Axys group.
14. A detailed description of the identification and characterization of compound 1 is the subject of another publication: Liang, A. M.; Light, D. R.; Kochanny, M.; Rumennik, G.; Trinh, L.; Lentz, D.; Post, J.; Morser, J.; Snider, M. Biochem. Pharmacol. In press.
15. i,app values are the mean of multiple determinations (n≥2). Standard deviations are <30% of the mean.
16. A similar series of neutral anthranilamide and diaminobenzene-derived fXa inhibitors has also been disclosed recently by researchers from Eli Lilly & Co.: Herron, D. K.; Goodson, T., Jr.; Wiley, M. R.; Weir, L. C.; Kyle, J. A.; Yee, Y. K.; Tebbe, A. L.; Tinsley, J. M.; Mendel D.; Masters, J.J.; Franciskovich, J. B.; Sawyer, J. S.; Beight, D. W.; Ratz, A. M.; Milot, G.; Hall, S. E.; Klimkowski, V. J.; Wikel, J. H.; Eastwood B. J.; Towner, R. D.; Gifford-Moore, D. S.; Craft, T. J.; Smith, G. F. J. Med. Chem. 43:2000;859. (b) Yee, Y. K.; Tebbe, A. L.; Linebarger, J. H.; Beight, D. W.; Craft, T. J.; Gifford-Moore, D.; Goodson, T. Jr.; Herron, D. K.; Klimkowski, V. J.; Kyle, J. A.; Sawyer, J. S.; Smith, G. F.; Tinsley, J. M.; Towner, R. D.; Weir, L.; Wiley, M. R. J. Med. Chem. 43:2000;873. (c) Masters, J.J.; Franciskovich, J.B.; Tinsley, J. M.; Campbell, C.; Craft T. J.; Froelich, L. L.; Gifford-Moore, D. S.; Hay, L. A.; Herron, D. K.; Klimkowski, V. J.; Kurz, K. D.; Metz, J. T.; Ratz, A. M.; Shuman, R. T.; Smith, G. F.; Smith, T.; Towner, R.D.; Wiley, M.R.; Wilson, A.; Yee, Y. K. J. Med. Chem. 43:2000;2087.
17. A similar series of neutral anthranilamide and diaminobenzene-derived fXa inhibitors has also been disclosed recently by researchers from Eli Lilly & Co.: Herron, D. K.; Goodson, T., Jr.; Wiley, M. R.; Weir, L. C.; Kyle, J. A.; Yee, Y. K.; Tebbe, A. L.; Tinsley, J. M.; Mendel D.; Masters, J.J.; Franciskovich, J. B.; Sawyer, J. S.; Beight, D. W.; Ratz, A. M.; Milot, G.; Hall, S. E.; Klimkowski, V. J.; Wikel, J. H.; Eastwood B. J.; Towner, R. D.; Gifford-Moore, D. S.; Craft, T. J.; Smith, G. F. J. Med. Chem. 43:2000;859. (b) Yee, Y. K.; Tebbe, A. L.; Linebarger, J. H.; Beight, D. W.; Craft, T. J.; Gifford-Moore, D.; Goodson, T. Jr.; Herron, D. K.; Klimkowski, V. J.; Kyle, J. A.; Sawyer, J. S.; Smith, G. F.; Tinsley, J. M.; Towner, R. D.; Weir, L.; Wiley, M. R. J. Med. Chem. 43:2000;873. (c) Masters, J.J.; Franciskovich, J.B.; Tinsley, J. M.; Campbell, C.; Craft T. J.; Froelich, L. L.; Gifford-Moore, D. S.; Hay, L. A.; Herron, D. K.; Klimkowski, V. J.; Kurz, K. D.; Metz, J. T.; Ratz, A. M.; Shuman, R. T.; Smith, G. F.; Smith, T.; Towner, R.D.; Wiley, M.R.; Wilson, A.; Yee, Y. K. J. Med. Chem. 43:2000;2087.
18. A similar series of neutral anthranilamide and diaminobenzene-derived fXa inhibitors has also been disclosed recently by researchers from Eli Lilly & Co.: Herron, D. K.; Goodson, T., Jr.; Wiley, M. R.; Weir, L. C.; Kyle, J. A.; Yee, Y. K.; Tebbe, A. L.; Tinsley, J. M.; Mendel D.; Masters, J.J.; Franciskovich, J. B.; Sawyer, J. S.; Beight, D. W.; Ratz, A. M.; Milot, G.; Hall, S. E.; Klimkowski, V. J.; Wikel, J. H.; Eastwood B. J.; Towner, R. D.; Gifford-Moore, D. S.; Craft, T. J.; Smith, G. F. J. Med. Chem. 43:2000;859. (b) Yee, Y. K.; Tebbe, A. L.; Linebarger, J. H.; Beight, D. W.; Craft, T. J.; Gifford-Moore, D.; Goodson, T. Jr.; Herron, D. K.; Klimkowski, V. J.; Kyle, J. A.; Sawyer, J. S.; Smith, G. F.; Tinsley, J. M.; Towner, R. D.; Weir, L.; Wiley, M. R. J. Med. Chem. 43:2000;873. (c) Masters, J.J.; Franciskovich, J.B.; Tinsley, J. M.; Campbell, C.; Craft T. J.; Froelich, L. L.; Gifford-Moore, D. S.; Hay, L. A.; Herron, D. K.; Klimkowski, V. J.; Kurz, K. D.; Metz, J. T.; Ratz, A. M.; Shuman, R. T.; Smith, G. F.; Smith, T.; Towner, R.D.; Wiley, M.R.; Wilson, A.; Yee, Y. K. J. Med. Chem. 43:2000;2087.
19. Adler, M.; Kochanny, M. J.; Ye, B.; Rumennik, G.; Light, D. R.; Biancalana, S.; Whitlaw, M. Biochemistry, in press.
20. Tucker T.J., Lumma W.C., Lewis S.D., Gardell S.J., Lucas B.J., Baskin E.P., Woltmann R., Lynch J.J., Lyle E.A., Appleby S.D., Chen I.-W., Dancheck K.B., Vacca J.P. J. Med. Chem. 40:1997;1565.
21. Lottenberg R., Christensen U., Jackson C.M., Coleman P.L. Methods Enzymol. 80:1981;341.
22. (a) Jordan S.P., Waxman L., Smith D.E., Vlasuk G.P. Biochem. 29:1990;11095.
23. (b) Morrison J.F. Biochim. Biophys. Acta. 185:1969;269.